Evaluation of the Effect of Favipiravir on QT Intervals in COVID-19 Patients with and without Diabetes Mellitus

Basit Öğe Kaydı
dc.contributor.authorDogan, Mustafa
dc.contributor.authorBaykiz, Derya
dc.contributor.authorYilmaz, Ibrahim
dc.contributor.authorKasim, Fatma Bahar Hacioglu
dc.contributor.authorBilir, Betul Ekiz
dc.contributor.authorBilir, Bulent
dc.date.accessioned2024-10-29T17:59:06Z
dc.date.available2024-10-29T17:59:06Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractObjective: To evaluate the effect of favipiravir administered to diabetic and non-diabetic COVID-19 patients on the QT/QTc interval. Study: Analytical study. Place and Duration of the Study: Republic of Turkey, Ministry of Health, State Hospital, Corlu, Tekirdag, Turkiye, from March to September 2021. Methodology: Electrocardiogram (ECG) analysis was performed on all participants (n=180) divided into four groups. Group 1 included only healthy volunteers. Group 2 included only cases diagnosed with T2DM. Group 3 included only severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) cases. Group 4 included cases diagnosed with both SARS and T2DM. Favipiravir was administered only to the cases in Group 3 and Group 4. In the cases that were administered favipiravir, the QT/QTc interval was calculated and recorded at different time intervals on the first and fifth days of the therapy. The difference between groups was determined by Tukeye's test after ANOVA. Pearson's correlation test was used to determine whether there was a linear relationship between two numericals. The alpha significance value was determined to be <0.05 in all statistical analyses. Results: When all groups were compared, it was seen that both QT and QTc values increased in Groups 3 and 4, which were administered favipiravir (p <0.05). Favipiravir may cause an increased risk of ventricular and atrial arrhythmias. Conclusion: Favipiravir may cause QT interval prolongation, particularly in SARS-Cov-2 patients diagnosed with T2DM.
dc.identifier.doi10.29271/jcpsp.2024.06.659
dc.identifier.endpage666
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.issue6en_US
dc.identifier.pmid38840347
dc.identifier.scopus2-s2.0-85195352029
dc.identifier.scopusqualityQ3
dc.identifier.startpage659
dc.identifier.urihttps://doi.org/10.29271/jcpsp.2024.06.659
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14629
dc.identifier.volume34
dc.identifier.wosWOS:001245509500007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherColl Physicians & Surgeons Pakistan
dc.relation.ispartofJcpsp-Journal of The College of Physicians and Surgeons Pakistan
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectDrug-induced long QT syndrome
dc.subjectIntra-infarct haemorrhage
dc.subjectFavipiravir
dc.subjectType 2 diabetes mellitus
dc.titleEvaluation of the Effect of Favipiravir on QT Intervals in COVID-19 Patients with and without Diabetes Mellitus
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu